DE69322645D1 - Expression rekombinanter fusionsproteine in attenuierten bakterien - Google Patents

Expression rekombinanter fusionsproteine in attenuierten bakterien

Info

Publication number
DE69322645D1
DE69322645D1 DE69322645T DE69322645T DE69322645D1 DE 69322645 D1 DE69322645 D1 DE 69322645D1 DE 69322645 T DE69322645 T DE 69322645T DE 69322645 T DE69322645 T DE 69322645T DE 69322645 D1 DE69322645 D1 DE 69322645D1
Authority
DE
Germany
Prior art keywords
expression
fusion proteins
recombinant fusion
attenuated bacteria
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69322645T
Other languages
English (en)
Other versions
DE69322645T2 (de
Inventor
Mohammed Khan
Carlos Hormaeche
Bernardo Camb Villarreal-Ramos
Steven Chatfield
Gordon Department Of Bi Dougan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Medeva Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929216317A external-priority patent/GB9216317D0/en
Priority claimed from GB939306398A external-priority patent/GB9306398D0/en
Application filed by Medeva Holdings BV filed Critical Medeva Holdings BV
Publication of DE69322645D1 publication Critical patent/DE69322645D1/de
Application granted granted Critical
Publication of DE69322645T2 publication Critical patent/DE69322645T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C12N9/1088—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69322645T 1992-07-31 1993-07-30 Expression rekombinanter fusionsproteine in attenuierten bakterien Expired - Fee Related DE69322645T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929216317A GB9216317D0 (en) 1992-07-31 1992-07-31 Vaccines
GB939306398A GB9306398D0 (en) 1993-03-26 1993-03-26 Vaccines
PCT/GB1993/001617 WO1994003615A1 (en) 1992-07-31 1993-07-30 Expression of recombinant fusion proteins in attenuated bacteria

Publications (2)

Publication Number Publication Date
DE69322645D1 true DE69322645D1 (de) 1999-01-28
DE69322645T2 DE69322645T2 (de) 1999-05-20

Family

ID=26301354

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69322645T Expired - Fee Related DE69322645T2 (de) 1992-07-31 1993-07-30 Expression rekombinanter fusionsproteine in attenuierten bakterien

Country Status (14)

Country Link
US (1) US6680182B1 (de)
EP (2) EP0652962B1 (de)
JP (1) JP3633933B2 (de)
KR (1) KR950702635A (de)
AT (1) ATE174628T1 (de)
AU (1) AU4719393A (de)
CA (1) CA2141427C (de)
DE (1) DE69322645T2 (de)
DK (1) DK0652962T3 (de)
ES (1) ES2127829T3 (de)
FI (1) FI950396A (de)
GR (1) GR3029498T3 (de)
NO (1) NO318018B1 (de)
WO (1) WO1994003615A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
CA2216425C (en) 1996-03-23 2003-08-12 The Research Foundation For Microbial Diseases Of Osaka University Tetanus toxin functional fragment antigen and tetanus vaccine
GB9608106D0 (en) * 1996-04-19 1996-06-26 Univ Newcastle Animal Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
GB9720033D0 (en) * 1997-09-19 1997-11-19 Medeva Plc Hepatitis B virus polypeptides
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9726233D0 (en) * 1997-12-11 1998-02-11 Medeva Europ Ltd Vaccines containing attenuated bacteria
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1790358A1 (de) 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Proteinkonstrukte designed zum Targeting und Lyse von Zellen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008023689A1 (fr) * 2006-08-21 2008-02-28 National University Corporation Kobe University Procédé de production d'une protéine de fusion
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
MX2010011938A (es) * 2008-05-02 2010-12-01 Idemitsu Kosan Co Vacuna para toxina bacteriana.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
HUE048573T2 (hu) * 2013-03-18 2020-08-28 Statens Seruminstitut Chlamydia SP. elleni vakcinák

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
AU613583B2 (en) * 1986-08-22 1991-08-08 Transgene S.A. Proteins and the method for preparing them, DNA sequences, antibodies and their application, poxviruses, transformed or infected cells, pharmaceutical compositions which are useful in the prevention of schistosomiasis and application by way of an agent possessing glutathione s-transferase activity
ATE109008T1 (de) * 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
US4970147A (en) * 1988-03-17 1990-11-13 The General Hospital Corporation Oxygen regulatable gene expression
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DE69002817T2 (de) * 1989-11-28 1993-12-09 Wellcome Found Vakzine.
CA2031468A1 (en) * 1989-12-08 1991-06-09 Mitchell S. Gross Malaria vaccine
FR2656626B1 (fr) * 1989-12-29 1994-08-12 Pasteur Institut Fragment peptidique comprenant une sequence issue de la proteine 28 kda de schistosoma mansoni et compositions vaccinantes et/ou therapeutiques comprenant ledit fragment.
KR100240182B1 (ko) * 1991-03-05 2000-01-15 레슬리 제인 에드워즈 재조합 단백질을 발헨하는 약독해진 박테리아를 함유하는 백신
SE468050C (sv) 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
AU710181B2 (en) * 1995-03-13 1999-09-16 Secretary Of State For Defence, The Vaccines for plague
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
US6142433A (en) * 1999-08-18 2000-11-07 Novelty Manufacturing Co. Window sash hanger

Also Published As

Publication number Publication date
EP0652962A1 (de) 1995-05-17
GR3029498T3 (en) 1999-05-28
FI950396A0 (fi) 1995-01-30
FI950396A (fi) 1995-01-30
NO950348L (no) 1995-03-28
CA2141427A1 (en) 1994-02-17
JPH08503602A (ja) 1996-04-23
WO1994003615A1 (en) 1994-02-17
ATE174628T1 (de) 1999-01-15
ES2127829T3 (es) 1999-05-01
NO950348D0 (no) 1995-01-30
AU4719393A (en) 1994-03-03
EP0863211A1 (de) 1998-09-09
EP0652962B1 (de) 1998-12-16
NO318018B1 (no) 2005-01-24
CA2141427C (en) 2008-07-22
US6680182B1 (en) 2004-01-20
KR950702635A (ko) 1995-07-29
DE69322645T2 (de) 1999-05-20
JP3633933B2 (ja) 2005-03-30
DK0652962T3 (da) 1999-08-23

Similar Documents

Publication Publication Date Title
DE69322645D1 (de) Expression rekombinanter fusionsproteine in attenuierten bakterien
ATE180280T1 (de) Expression rekombinanter proteine in attenuierten bakterien
ES2087323T3 (es) Metodo para producir peptidos exentos de cisteina.
DE69333673D1 (de) Epitope von Stress Proteinen
FI864427A0 (fi) Menetelmä polypeptidin valmistamiseksi, joka on komplementaarinen ainakin osalle alkuperäistä peptidiä tai proteiinia, ja komplementaarisen polypeptidin käyttö
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
PT755447E (pt) Proteinas recombinantes de hemaglutinina filamentosa de bordetella particularmente bordetella pertussis metodo para a sua producao e suas aplicaoes na producao de proteinas estranhas ou de principios activos para vacinas
MX9207459A (es) Anticuerpos humanizados reactivos con gpiib/iiia.
ATE150791T1 (de) Proteinstruktur des pflanzlichen toxins gelonin
ES2062759T3 (es) Procedimiento de purificacion de polipeptidos recombinantes.
ATE120492T1 (de) Fv antikörperfragment-herstellung.
DK447784A (da) Immuninterferon
DE59203874D1 (de) Schizosaccharomyces-spezifische Polypeptide.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PEPTIDE THERAPEUTICS LTD., CAMBRIDGE, GB

8339 Ceased/non-payment of the annual fee